Under the influence of tumor-derived factors such as VEGF, ECs can selectively upregulate inhibitory receptors involved in T-cell activation, including PD-L1, PD-L2, IDO-1, IL-6, and IL-10 (31). The gene discussed is CD274; the disease is neoplasm.